Citi analyst Robyn Karnauskas lowered her price target for Biogen to $290 saying Tecfidera "is an unanswered question and a big risk to the stock." The analyst is unsure what the generic Gilenya impact will be on Tecfidera. Biogen shares may not be at a bad entry point for long-term investors, but "we don't think this is where people need to be over the next year," Karnauskas tells investors in research note. She believes the key issue for the shares is the Alzheimer's program and expects data late in 2019 or early 2020. The analyst keeps a Neutral rating on Biogen.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here